Recap of eAJKD’s coverage of the 2013 American Transplant Congress
Check out all of the coverage of this year’s American Transplant Congress by eAJKD’s Dr. Vinay Nair below: Alemtuzumab Induction and Belatacept-Based Immunosuppression in [...]
ATC2013
ATC 2013: Everolimus in Kidney Transplantation – HERAKLES trial
Everolimus in Kidney Transplantation: HERAKLES trial Many studies have been conducted with the intention of reducing exposure to calcineurin inhibitors. Avoiding calcineurin [...]
ATC 2013: Simultaneous Liver Kidney Transplantation – Stealing or Saving?
Simultaneous Liver Kidney Transplantation: Stealing or Saving? That was the topic of a hotly debated 3 lecture session presented by Dr. Nadim from the University of Southern [...]
ATC 2013: Development of De Novo HLA Antibodies After Transplantation – Results from the CTOT02 Study
Development of De Novo HLA antibodies after transplantation: Results from the CTOT02 Study. CTOT02 is a large prospective multi-center trial set in 2 phases. Phase 1 involved [...]
ATC 2013: Long-term Risk of ESRD in Kidney Donors – Is There Really No Harm?
Long-term Risk of ESRD in Kidney Donors: Is There Really No Harm? One of the most shocking presentations in the ATC was given during the last plenary session. Dr. Muzaale [...]
ATC 2013: Everolimus in Liver Transplant Patients Preserves GFR. PROTECT Study – 35 Month Update
Everolimus in liver transplant patients preserves GFR. PROTECT study – 35 month update. Long term exposure to calcineurin inhibitors (CNI) is nephrotoxic. It is [...]
ATC 2013: Does Adding Rituximab to IVIg and Plasmapheresis Improve Outcome of AMR? 1-Yr Results of RITUX-ERAH Study
Does adding rituximab to IVIg and plasmapheresis improve outcome of antibody mediated rejection? One year results of the RITUX-ERAH study. In transplant and nephrology, the [...]
ATC 2013: The Impact of Pre-donation Weight Loss on Post-donation Outcome
The Impact of Pre-donation Weight Loss on Post-donation Outcome. Dr. Marsden from Cardiff transplant unit, University of Wales, shared data on donor obesity from their living [...]
ATC 2013: Eculizumab Therapy for Chronic Antibody Mediated Rejection
Eculizumab Therapy for Chronic Antibody Mediated Rejection Chronic antibody mediated rejection (AMR) is currently a major problem in kidney transplantation. Chronic AMR [...]
ATC 2013: Alemtuzumab Induction and Belatacept-Based Immunosuppression in Kidney Transplant Recipients
ATC abstract presentation: Alemtuzumab Induction and Belatacept-Based Immunosuppression in Renal Transplant Recipients: Peripheral Dynamics of T and B cell Populations with [...]